129 related articles for article (PubMed ID: 22271877)
1. High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y; Shim HS; Park MS; Kim JH; Ha SJ; Kim SH; Cho BC
Clin Cancer Res; 2012 Mar; 18(6):1760-8. PubMed ID: 22271877
[TBL] [Abstract][Full Text] [Related]
2. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Hirsch FR; Varella-Garcia M; McCoy J; West H; Xavier AC; Gumerlock P; Bunn PA; Franklin WA; Crowley J; Gandara DR;
J Clin Oncol; 2005 Oct; 23(28):6838-45. PubMed ID: 15998906
[TBL] [Abstract][Full Text] [Related]
3. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Cappuzzo F; Varella-Garcia M; Shigematsu H; Domenichini I; Bartolini S; Ceresoli GL; Rossi E; Ludovini V; Gregorc V; Toschi L; Franklin WA; Crino L; Gazdar AF; Bunn PA; Hirsch FR
J Clin Oncol; 2005 Aug; 23(22):5007-18. PubMed ID: 16051952
[TBL] [Abstract][Full Text] [Related]
4. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas.
Chung CH; Ely K; McGavran L; Varella-Garcia M; Parker J; Parker N; Jarrett C; Carter J; Murphy BA; Netterville J; Burkey BB; Sinard R; Cmelak A; Levy S; Yarbrough WG; Slebos RJ; Hirsch FR
J Clin Oncol; 2006 Sep; 24(25):4170-6. PubMed ID: 16943533
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials.
Petrelli F; Borgonovo K; Cabiddu M; Barni S
Clin Lung Cancer; 2012 Mar; 13(2):107-14. PubMed ID: 22056888
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
[TBL] [Abstract][Full Text] [Related]
7. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
8. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
[TBL] [Abstract][Full Text] [Related]
9. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Felip E; Rojo F; Reck M; Heller A; Klughammer B; Sala G; Cedres S; Peralta S; Maacke H; Foernzler D; Parera M; Möcks J; Saura C; Gatzemeier U; Baselga J
Clin Cancer Res; 2008 Jun; 14(12):3867-74. PubMed ID: 18559607
[TBL] [Abstract][Full Text] [Related]
10. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations detected by denaturing high-performance liquid chromatography in nonsmall cell lung cancer: impact on response to therapy with epidermal growth factor receptor-tyrosine kinase inhibitors.
Cohen V; Agulnik JS; Ang C; Kasymjanova G; Batist G; Small D; Brandao G; Chong G; Miller WH
Cancer; 2010 Sep; 116(18):4309-17. PubMed ID: 20549828
[TBL] [Abstract][Full Text] [Related]
12. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
[TBL] [Abstract][Full Text] [Related]
13. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Jänne PA; Johnson BE
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4416s-4420s. PubMed ID: 16857820
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
[TBL] [Abstract][Full Text] [Related]
15. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer.
Lee JK; Park HS; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS; Kim WH; Bang YJ
Cancer; 2012 Jul; 118(14):3579-86. PubMed ID: 22086654
[TBL] [Abstract][Full Text] [Related]
16. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib.
Agulnik M; da Cunha Santos G; Hedley D; Nicklee T; Dos Reis PP; Ho J; Pond GR; Chen H; Chen S; Shyr Y; Winquist E; Soulieres D; Chen EX; Squire JA; Marrano P; Kamel-Reid S; Dancey J; Siu LL; Tsao MS
J Clin Oncol; 2007 Jun; 25(16):2184-90. PubMed ID: 17538163
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.
Ameratunga M; Pavlakis N; Gebski V; Broad A; Khasraw M
Asia Pac J Clin Oncol; 2014 Sep; 10(3):273-8. PubMed ID: 25135201
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports.
Liu Y; Zhang Y; Zhang L; Liu B; Wang Y; Zhou X; Li Y; Zhao Q; Gong Y; Zhou L; Zhu J; Ding Z; Wang J; Peng F; Huang M; Li L; Ren L; Lu Y
Oncotarget; 2017 Jul; 8(30):49680-49688. PubMed ID: 28591695
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Hirsch FR; Varella-Garcia M; Bunn PA; Di Maria MV; Veve R; Bremmes RM; Barón AE; Zeng C; Franklin WA
J Clin Oncol; 2003 Oct; 21(20):3798-807. PubMed ID: 12953099
[TBL] [Abstract][Full Text] [Related]
20. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]